Eledon Pharmaceuticals

Yahoo Finance • 7 days ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upco... Full story

Yahoo Finance • last month

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Can... Full story

Yahoo Finance • 2 months ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in k... Full story

Yahoo Finance • 2 months ago

Stay updated with the stocks that are on the move in today's after-hours session.

The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. [postmarket] AFTER HOURS GAINERS TICKER CHA... Full story

Yahoo Finance • 2 months ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports th... Full story

Yahoo Finance • 3 months ago

Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of r... Full story

Yahoo Finance • 3 months ago

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: EL... Full story

Yahoo Finance • 3 months ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am ET. The event will fe... Full story

Yahoo Finance • 6 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subje... Full story

Yahoo Finance • 7 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcomi... Full story

Yahoo Finance • 8 months ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets CD40 ligand (CD40L) with potential to im... Full story

Yahoo Finance • 8 months ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., Chief Scientific Officer and P... Full story

Yahoo Finance • 2 years ago

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming NobleCo... Full story

Yahoo Finance • 2 years ago

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Ph... Full story

Yahoo Finance • 2 years ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming Jefferi... Full story

Yahoo Finance • 2 years ago

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m2at all reported time points after day 90 support... Full story

Yahoo Finance • 2 years ago

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s c... Full story

Yahoo Finance • 2 years ago

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

IRVINE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will present a poster at the American Society of Nephrology’s upcoming Kidney Week 2023 Annual Meet... Full story

Yahoo Finance • 2 years ago

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors. Dr. Kirk is internationally recognize... Full story

Yahoo Finance • 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Landmark cardiac xenotransplantation procedure conducted at University of Maryland Medical Center Tegoprubart, administered investigationally to prevent organ rejection post-transplant, targets the CD40L pathway known to play an essential... Full story